Contraceptive Services/Primary Care to Prevent Birth Defects
Contraceptive Services/Primary Care to Prevent Birth Defects
批准号:
7665135
负责人:
ELEANOR Bimla SCHWARZ
金额:
$12.62万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-09 至 2011-07-31
关键词:
AddressAgeAmbulatory CareAwarenessBiometryBirthCaliforniaCharacteristicsChildClinicClinical ResearchCohort StudiesComplementCongenital AbnormalityContraceptive AgentsContraceptive methodsContractsConvulsantsCounselingCross-Sectional StudiesDataData AnalysesData CollectionData SetDatabasesDefectDevelopmentDimensionsDisciplineEnsureEpidemiologyEthnic OriginEvaluationFamilyFamily Planning ProgramsFemaleFemale of child bearing ageFrequenciesFundingFutureGeneral PractitionersGoalsGynecologyHealthcareHigh Risk WomanIndividualInfantInterventionKnowledgeLaboratoriesMedicalMedicineMentored Patient-Oriented Research Career Development AwardMentorsMentorshipMissionNational Ambulatory Medical Care SurveyNursing StaffOutcomePatientsPersonsPharmaceutical PreparationsPharmacy facilityPhysiciansPlanned PregnancyPopulationPregnancyPregnancy TestsPrevalencePreventionPrimary Care PhysicianPrimary Health CarePrincipal InvestigatorProviderPsyche structureRandomizedReminder SystemsResearchResearch PersonnelResearch Project GrantsResearch TrainingRiskRisk AssessmentSafetyServicesSocial SciencesSurveysSystemTetracyclinesTimeUnited StatesUnited States National Institutes of HealthWomanWorkadministrative databasebasecareercontextual factorscontraceptive practicedesigneffective interventionexperiencehealth care deliveryhigh riskimprovedmedical specialtiespatient orientedpatient safetypreventprogramsreproductivereproductive epidemiologyskillsstemtrendunintended pregnancy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Each year, 150,000 infants (1% - 3% of all U.S. births) are born with some form of physical or mental birth defect. As it is sometimes necessary to treat women with medications that cause birth defects, physicians must counsel women about medication risks and contraceptive options. In a recent analysis of the 1998-2000 National Ambulatory Medical Care Surveys, I found that generalist physicians provide ambulatory care to 45% of women using potentially teratogenic medications, but rarely (less than 20% of the time) provide contraceptive counseling. The reasons why many generalist physicians do not provide this counseling are not known. I seek a K23 award to strengthen my abilities to develop effective interventions to prevent birth defects resulting from inappropriate use of teratogenic medications by women of childbearing age. Specifically, I propose to conduct a retrospective cohort study of 650,000 women of reproductive age served by Northern California Kaiser Permanente pharmacies to identify which potentially teratogenic medications are most frequently prescribed without use of highly effective contraception (Aim 1); to conduct a cross sectional study of gaps in knowledge of primary care physicians that may contribute to unsafe prescription of teratogenic medications (Aim 2); and to evaluate the effect of a previously implemented clinic-based intervention to increase physician awareness of patients' contraceptive practices on unsafe prescription of teratogenic medications among approximately 190,000 women of childbearing age (Aim 3). To achieve these aims, I have assembled a mentoring committee whose expertise spans the relevant disciplines of epidemiology and general medicine (Drs. Grady and Gonazales) and gynecology (Dr. Darney). In addition, I have scientific advisors with expertise in reproductive epidemiology (Dr. Carmichael), reproductive social science (Dr. Joffe), patient safety (Dr. Wachter), survey instrument design (Dr. Stewart), biostatistics (Dr.Vittinghoff), risk assessment (Dr. Bindman), and use of the Kaiser Permanente databases (Dr. Shaber).Their mentorship, as well as a focused training and research plan facilitated by a K23 award, will enable me to achieve my goal of developing an independent career in patient-oriented clinical research, focused on facilitating contraceptive service provision to limit adverse birth outcomes, while furthering the NICHD's mission of ensuring that every person is born healthy and wanted.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Disseminating PCOR findings to Reduce Racial Disparities in Surgical Sterilization
-
批准号:10650016
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2023
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
Improving the Safe Use of Isotretinoin
-
批准号:8538243
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2011
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
Improving the Safe Use of Isotretinoin
-
批准号:8302846
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2011
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
Harnessing Health IT to Prevent Medication-Induced Birth Defects
-
批准号:7493505
-
项目类别:
-
资助金额:$39.84万
-
财政年份:2007
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
Harnessing Health IT to Prevent Medication-Induced Birth Defects
-
批准号:7688031
-
项目类别:
-
资助金额:$40.03万
-
财政年份:2007
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
Harnessing Health IT to Prevent Medication-Induced Birth Defects
-
批准号:7359394
-
项目类别:
-
资助金额:$39.98万
-
财政年份:2007
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
Contraceptive Services/Primary Care to Prevent Birth Defects
-
批准号:7932196
-
项目类别:
-
资助金额:$12.62万
-
财政年份:2006
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
Contraceptive Services/Primary Care Prevent Birth Defect
-
批准号:7014153
-
项目类别:
-
资助金额:$12.63万
-
财政年份:2006
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
Contraceptive Services/Primary Care to Prevent Birth Defects
-
批准号:7454490
-
项目类别:
-
资助金额:$12.62万
-
财政年份:2006
-
负责人:ELEANOR Bimla SCHWARZ
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: